3 results
The primary objective is to determine the efficacy (as measured by pulmonaryfunction) and safety of CNTO 888 in subjects with IPF. The major secondary objectives are to assess theeffect of CNTO 888 on measures of disease progression, to assess the…
2.1.1 Primary Objective:To evaluate the difference in the rates of graded pulmonary exacerbations in patients with bronchiectasis treated with inhaled mannitol compared with placebo control2.1.2 Secondary Objectives:EfficacyTo evaluate the…
Primary ObjectivesTo assess the safety of 2 fixed doses of EVP-6124 (2 or 3 mg daily) for up to 52 weeks in subjects withAlzheimer*s disease (AD) who complete (Day 182) studies EVP-6124-024 or EVP-6124-025Secondary ObjectivesTo assess the duration…